Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; 55 of the 70 sources its claims cite were checked for support.

Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests

Open access

Abstract

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying patients who could benefit from these treatments becomes critical. In this study, we evaluated whether a precise blood test could perform as well as established cerebrospinal fluid (CSF) tests in detecting amyloid-β (Aβ) plaques and tau tangles. Plasma %p-tau217 was analyzed by mass spectrometry in the Swedish BioFINDER-2 cohort (n=1,422) and the US Knight ADRC cohort (n=337). Matched CSF samples were analyzed with clinically used and FDA-approved automated immunoassays for Aβ42/40 and p-tau181/Aβ42.

Overview

CoChat Summary

TL;DR

Plasma %p-tau217, measured by mass spectrometry, performed as well as or better than clinically used FDA-approved CSF tests for identifying Aβ and tau PET positivity in two independent cohorts. In cognitively impaired participants, performance improved further with a two-cutoffs approach, reaching about 95% accuracy/PPV for Aβ status in most patients.

Key findings

  • In the full cohorts, plasma %p-tau217 classified Aβ PET status with very high accuracy: AUC 0.97 in BioFINDER-2 and 0.97 in Knight ADRC, clinically equivalent to CSF biomarker ratios.
  • For tau PET status, plasma %p-tau217 was superior to CSF tests in the full cohorts: AUC 0.95 vs 0.93/0.88 in BioFINDER-2 and 0.98 vs 0.96/0.90 in Knight ADRC.
  • In cognitively impaired participants, plasma %p-tau217 predicted Aβ PET status with 90% accuracy in BioFINDER-2 and 94% accuracy in Knight ADRC, with PPV/NPV around 89%/89% or higher; it was clinically equivalent to CSF tests for Aβ.
  • Using two cutoffs improved Aβ PET prediction in cognitively impaired BioFINDER-2 participants to 95% accuracy, 95% PPV, and 96% NPV for plasma %p-tau217, with 16% intermediate values; for tau PET, plasma %p-tau217 reached 94% accuracy and was superior to CSF tests.

Methods

  • Observational comparison across two independent cohorts: BioFINDER-2 (n = 1,422) in Sweden and Knight ADRC (n = 337) in the US; main analyses focused on cognitively impaired participants, including MCI and dementia.
  • Plasma %p-tau217 was measured by LC–MS/HRMS; CSF biomarkers were measured with clinical/FDA-approved automated immunoassays (Roche Elecsys in BioFINDER-2, Fujirebio Lumipulse in Knight ADRC).
  • Diagnostic performance was evaluated against Aβ PET positivity, tau PET positivity, and clinical AD diagnosis using ROC curves/AUC, plus accuracy, PPV, and NPV; equivalence was defined by 95% CI of the mean difference including zero.

Limitations

  • The paper states that the Knight ADRC cognitive-impairment subgroup was relatively small, and there was no sufficiently large group with both antemortem biomarker data and postmortem data.
  • The paper states that minoritized populations were not well enough represented, and that future studies should test broader primary care populations.
  • Evident from the text: the study is observational and uses PET/clinical diagnosis as reference standards, so it does not test whether using the blood assay improves patient outcomes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-024-02869-z

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Concordance of fluid and imaging biomarkers of amyloid and tau pathologies. a,b,d,e, Concordance of fluid biomarkers with Aβ and tau PET positivity in BioFINDER-2 (a and d) and Knight ADRC (b and e) participants. ROC curves including all participants are included in the first row. AUCs for all, cognitively impaired and cognitively unimpaired groups are shown in the next three columns, respectively. c,f, Bootstrapped differences (n = 1,000 resamples with replacement stratifying by the output) between the statistics using plasma %p-tau217 (reference) and CSF biomarkers are shown in c and f for both the BioFINDER-2 cohort (left) and the Knight ADRC (right) cohort. The horizontal dashed line is plotted at zero, representing the lack of difference between plasma and CSF biomarkers. We considered plasma and CSF biomarkers clinically equivalent if the 95% CI of the mean difference included zero and clinically superior if it did not include zero and favored plasma (>0). Dots and error bars represent the actual statistic and 95% CI (from bootstrapped n = 1,000 samples with replacement), respectively. Vertical dashed lines represent the maximal AUC value possible (1). Aβ PET positivity was assessed as Centiloids ≥ 37. Tau PET positivity was assessed using previously validated in-house thresholds (SUVR > 1.32 in Braak I–IV for both cohorts). AUC, area under the curve; CI, cognitively impaired; CSF, cerebrospinal fluid; CU, cognitively unimpaired; SUVR, standardized uptake value ratio; CI, confidence interval.
Fig. 1 Concordance of fluid and imaging biomarkers of amyloid and tau pathologies. a,b,d,e, Concordance of fluid biomarkers with Aβ and tau PET positivity in BioFINDER-2 (a and d) and Knight ADRC (b and e) participants. ROC curves including all participants are included in the first row. AUCs for all, cognitively impaired and cognitively unimpaired groups are shown in the next three columns, respectively. c,f, Bootstrapped differences (n = 1,000 resamples with replacement stratifying by the output) between the statistics using plasma %p-tau217 (reference) and CSF biomarkers are shown in c and f for both the BioFINDER-2 cohort (left) and the Knight ADRC (right) cohort. The horizontal dashed line is plotted at zero, representing the lack of difference between plasma and CSF biomarkers. We considered plasma and CSF biomarkers clinically equivalent if the 95% CI of the mean difference included zero and clinically superior if it did not include zero and favored plasma (>0). Dots and error bars represent the actual statistic and 95% CI (from bootstrapped n = 1,000 samples with replacement), respectively. Vertical dashed lines represent the maximal AUC value possible (1). Aβ PET positivity was assessed as Centiloids ≥ 37. Tau PET positivity was assessed using previously validated in-house thresholds (SUVR > 1.32 in Braak I–IV for both cohorts). AUC, area under the curve; CI, cognitively impaired; CSF, cerebrospinal fluid; CU, cognitively unimpaired; SUVR, standardized uptake value ratio; CI, confidence interval.CC BY · PubMed Central
Fig. 2 Comparison among fluid biomarkers on predicting Aβ PET positivity in cognitively impaired patients of the BioFINDER-2 cohort. a,b, Prediction of Aβ PET positivity in cognitively impaired participants (n = 304) from the BioFINDER-2 cohort, using a single-cutoff (a) and a two-cutoffs (b) approach, respectively. In the first approach, the threshold was calculated, maximizing sensitivity and fixing specificity at 90%. In the second approach, the lower threshold was obtained by maximizing specificity with sensitivity fixed at 95%, whereas the upper threshold was obtained by maximizing sensitivity while fixing specificity at 95%. Participants who fall between these two cutoffs were classified in the intermediate group. Dots and error bars represent the actual statistic and 95% CI (from bootstrapped n = 1,000 samples with replacement), respectively. c, Bootstrapped differences (n = 1,000 resamples with replacement stratifying by the output) between the statistics using plasma %p-tau217 (reference) and CSF biomarkers are shown in c for both single cutoff and two cutoffs. The horizontal dashed line is plotted at zero, representing the lack of difference between plasma and CSF biomarkers. We considered plasma and CSF biomarkers clinically equivalent if the 95% CI of the mean difference included zero and clinically superior if it did not include zero and favored plasma (>0). Differences in the number of participants in the intermediate group were scaled to a maximum of 1 to be comparable with the other differences. Dots and error bars represent the mean and 95% CI estimate from a bootstrapped sample. Vertical dashed lines represent the maximal statistical value possible (1). For the intermediate value plots, colored bars represent the actual percentage and the error bar the 95% CI. d, Histograms represent the distribution of the data colored by the imaging biomarker status. The vertical black line represents the threshold derived from the first approach (a), and red lines represent the lower and upper thresholds from the second approach (b). Aβ PET positivity was assessed as Centiloids ≥ 37. CSF, cerebrospinal fluid; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
Fig. 2 Comparison among fluid biomarkers on predicting Aβ PET positivity in cognitively impaired patients of the BioFINDER-2 cohort. a,b, Prediction of Aβ PET positivity in cognitively impaired participants (n = 304) from the BioFINDER-2 cohort, using a single-cutoff (a) and a two-cutoffs (b) approach, respectively. In the first approach, the threshold was calculated, maximizing sensitivity and fixing specificity at 90%. In the second approach, the lower threshold was obtained by maximizing specificity with sensitivity fixed at 95%, whereas the upper threshold was obtained by maximizing sensitivity while fixing specificity at 95%. Participants who fall between these two cutoffs were classified in the intermediate group. Dots and error bars represent the actual statistic and 95% CI (from bootstrapped n = 1,000 samples with replacement), respectively. c, Bootstrapped differences (n = 1,000 resamples with replacement stratifying by the output) between the statistics using plasma %p-tau217 (reference) and CSF biomarkers are shown in c for both single cutoff and two cutoffs. The horizontal dashed line is plotted at zero, representing the lack of difference between plasma and CSF biomarkers. We considered plasma and CSF biomarkers clinically equivalent if the 95% CI of the mean difference included zero and clinically superior if it did not include zero and favored plasma (>0). Differences in the number of participants in the intermediate group were scaled to a maximum of 1 to be comparable with the other differences. Dots and error bars represent the mean and 95% CI estimate from a bootstrapped sample. Vertical dashed lines represent the maximal statistical value possible (1). For the intermediate value plots, colored bars represent the actual percentage and the error bar the 95% CI. d, Histograms represent the distribution of the data colored by the imaging biomarker status. The vertical black line represents the threshold derived from the first approach (a), and red lines represent the lower and upper thresholds from the second approach (b). Aβ PET positivity was assessed as Centiloids ≥ 37. CSF, cerebrospinal fluid; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.CC BY · PubMed Central
Fig. 3 Comparison among fluid biomarkers on predicting tau PET positivity in cognitively impaired patients of the BioFINDER-2 cohort. a,b, Prediction of tau PET positivity in cognitively impaired participants from the BioFINDER-2 cohort (n = 663), using a single-cutoff (a) and a two-cutoffs (b) approach, respectively. In the first approach, the threshold was calculated, maximizing sensitivity and fixing specificity at 90%. In the second approach, the lower threshold was obtained by maximizing specificity with sensitivity fixed at 95%, whereas the upper threshold was obtained by maximizing sensitivity and fixing specificity at 95%. Participants who fall between these two cutoffs were classified in the intermediate group. Dots and error bars represent the actual statistic and 95% CI, respectively. Vertical dashed lines represent the maximal statistical value possible (1). For the intermediate value plots, colored bars represent the actual percentage and the error bar the 95% CI. c, Bootstrapped differences (n = 1,000 resamples with replacement stratifying by the output) between the statistics using plasma %p-tau217 (reference) and CSF biomarkers are shown in c for both single cutoff and two cutoffs. The horizontal dashed line is plotted at zero, representing the lack of difference between plasma and CSF biomarkers. We considered plasma and CSF biomarkers clinically equivalent if the 95% CI of the mean difference included zero. Differences in the number of participants in the intermediate group were scaled to a maximum of 1 to be comparable with the other differences. Dots and error bars represent the mean and 95% CI estimate from a bootstrapped sample. d, Histograms represent the distribution of the data colored by the imaging biomarker status. The vertical black line represents the threshold derived from the first approach (a), and red lines represent the lower and upper thresholds from the second approach (b). Tau PET positivity was assessed using an in-house previously validated threshold (SUVR > 1.32). Three individuals were excluded from the histograms in d (only for visualization purposes) due to very low values of plasma %p-tau217. CSF, cerebrospinal fluid; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; SUVR, standardized uptake value ratio.
Fig. 3 Comparison among fluid biomarkers on predicting tau PET positivity in cognitively impaired patients of the BioFINDER-2 cohort. a,b, Prediction of tau PET positivity in cognitively impaired participants from the BioFINDER-2 cohort (n = 663), using a single-cutoff (a) and a two-cutoffs (b) approach, respectively. In the first approach, the threshold was calculated, maximizing sensitivity and fixing specificity at 90%. In the second approach, the lower threshold was obtained by maximizing specificity with sensitivity fixed at 95%, whereas the upper threshold was obtained by maximizing sensitivity and fixing specificity at 95%. Participants who fall between these two cutoffs were classified in the intermediate group. Dots and error bars represent the actual statistic and 95% CI, respectively. Vertical dashed lines represent the maximal statistical value possible (1). For the intermediate value plots, colored bars represent the actual percentage and the error bar the 95% CI. c, Bootstrapped differences (n = 1,000 resamples with replacement stratifying by the output) between the statistics using plasma %p-tau217 (reference) and CSF biomarkers are shown in c for both single cutoff and two cutoffs. The horizontal dashed line is plotted at zero, representing the lack of difference between plasma and CSF biomarkers. We considered plasma and CSF biomarkers clinically equivalent if the 95% CI of the mean difference included zero. Differences in the number of participants in the intermediate group were scaled to a maximum of 1 to be comparable with the other differences. Dots and error bars represent the mean and 95% CI estimate from a bootstrapped sample. d, Histograms represent the distribution of the data colored by the imaging biomarker status. The vertical black line represents the threshold derived from the first approach (a), and red lines represent the lower and upper thresholds from the second approach (b). Tau PET positivity was assessed using an in-house previously validated threshold (SUVR > 1.32). Three individuals were excluded from the histograms in d (only for visualization purposes) due to very low values of plasma %p-tau217. CSF, cerebrospinal fluid; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; SUVR, standardized uptake value ratio.CC BY · PubMed Central
Extended Data Fig. 1 Comparison among fluid biomarkers on predicting Aβ PET visual read positivity in cognitively impaired patients of the BioFINDER-2 cohort with in-bag estimates. Prediction of Aβ PET visual read positivity in cognitively impaired participants from the BioFINDER-2 cohort, using a single cut-off (a) and two cut-offs (b) approaches, respectively. In the first approach, the cut-off was calculated maximizing sensitivity fixing specificity at 90%. In the second approach, the lower cut-off was obtained by maximizing specificity with sensitivity fixed at 95%, whereas the upper cut-off was obtained by maximizing sensitivity fixing specificity at 95%. Participants that fall between these two cut-offs were classified in the intermediate group. Dots and error bars represent the actual statistic and 95%CI, respectively. Bootstrapped differences (n = 1,000 resamples with replacement stratifying by the output) between the statistics using plasma %p-tau217 (reference) and CSF biomarkers are shown in (c) for both single and two cut-offs. A horizontal dashed line is plotted at zero representing the lack of difference between plasma and CSF biomarkers. We considered plasma and CSF biomarkers clinically equivalent if the 95%CI of the mean difference included zero and clinically superior if it did not include zero and favored plasma (>0). Differences in number of participants in the intermediate group have been scaled to a maximum of one to be comparable to the other differences. Dots and error bars represent the mean and 95%CI estimate from a bootstrapped sample. Vertical dashed lines represent the maximal statistical value possible (1). For the intermediate values plots, coloured bars represent the actual percentage and error bar the 95%CI. Histograms (d) represent the distribution of the data coloured by the imaging biomarker status (coloured represent the positive group). Vertical black line represents the cut-off derived from the first approach (a), and red lines represent the lower and upper cut-offs from the second approach (B). Abbreviations: Aβ, amyloid-β, CI, confidence interval; CSF, cerebrospinal fluid; NPV, negative predictive value; PPV, positive predictive value.
Extended Data Fig. 1 Comparison among fluid biomarkers on predicting Aβ PET visual read positivity in cognitively impaired patients of the BioFINDER-2 cohort with in-bag estimates. Prediction of Aβ PET visual read positivity in cognitively impaired participants from the BioFINDER-2 cohort, using a single cut-off (a) and two cut-offs (b) approaches, respectively. In the first approach, the cut-off was calculated maximizing sensitivity fixing specificity at 90%. In the second approach, the lower cut-off was obtained by maximizing specificity with sensitivity fixed at 95%, whereas the upper cut-off was obtained by maximizing sensitivity fixing specificity at 95%. Participants that fall between these two cut-offs were classified in the intermediate group. Dots and error bars represent the actual statistic and 95%CI, respectively. Bootstrapped differences (n = 1,000 resamples with replacement stratifying by the output) between the statistics using plasma %p-tau217 (reference) and CSF biomarkers are shown in (c) for both single and two cut-offs. A horizontal dashed line is plotted at zero representing the lack of difference between plasma and CSF biomarkers. We considered plasma and CSF biomarkers clinically equivalent if the 95%CI of the mean difference included zero and clinically superior if it did not include zero and favored plasma (>0). Differences in number of participants in the intermediate group have been scaled to a maximum of one to be comparable to the other differences. Dots and error bars represent the mean and 95%CI estimate from a bootstrapped sample. Vertical dashed lines represent the maximal statistical value possible (1). For the intermediate values plots, coloured bars represent the actual percentage and error bar the 95%CI. Histograms (d) represent the distribution of the data coloured by the imaging biomarker status (coloured represent the positive group). Vertical black line represents the cut-off derived from the first approach (a), and red lines represent the lower and upper cut-offs from the second approach (B). Abbreviations: Aβ, amyloid-β, CI, confidence interval; CSF, cerebrospinal fluid; NPV, negative predictive value; PPV, positive predictive value.CC BY · PubMed Central
Extended Data Fig. 2 Continuous Aβ and tau PET measures by categorized fluid biomarkers groups. Comparison between categorised fluid biomarkers levels and continuous measures of Aβ- (Centiloids, a, b) and tau PET (SUVR, c, d) quantification. Fluid biomarkers were categorised using the two-cut-off approach. The lower cut-off was obtained by maximizing specificity with sensitivity fixed at 95%, whereas the upper cut-off was obtained by maximizing sensitivity fixing specificity at 95%. Participants that fall between these two cut-offs were classified in the intermediate group. Dots represent individual participants. In all cases, central band of the boxplot represents the median of the group, the lower and upper hinges correspond to the first and third quartiles, and the whiskers represent the maximum/minimum value or the 1.5 IQR from the hinge, whatever is lower. Horizontal dashed lines represent the cut-off of positivity for each imaging marker (Aβ PET: ≥37 Centiloids, Tau PET: >1.32 SUVR for both cohorts). Abbreviations: Aβ, amyloid-β; CI, confidence interval; CSF, cerebrospinal fluid; IQR, inter-quantile range; NPV, negative predictive value; PPV, positive predictive value; SUVR, standardized uptake value ratio.
Extended Data Fig. 2 Continuous Aβ and tau PET measures by categorized fluid biomarkers groups. Comparison between categorised fluid biomarkers levels and continuous measures of Aβ- (Centiloids, a, b) and tau PET (SUVR, c, d) quantification. Fluid biomarkers were categorised using the two-cut-off approach. The lower cut-off was obtained by maximizing specificity with sensitivity fixed at 95%, whereas the upper cut-off was obtained by maximizing sensitivity fixing specificity at 95%. Participants that fall between these two cut-offs were classified in the intermediate group. Dots represent individual participants. In all cases, central band of the boxplot represents the median of the group, the lower and upper hinges correspond to the first and third quartiles, and the whiskers represent the maximum/minimum value or the 1.5 IQR from the hinge, whatever is lower. Horizontal dashed lines represent the cut-off of positivity for each imaging marker (Aβ PET: ≥37 Centiloids, Tau PET: >1.32 SUVR for both cohorts). Abbreviations: Aβ, amyloid-β; CI, confidence interval; CSF, cerebrospinal fluid; IQR, inter-quantile range; NPV, negative predictive value; PPV, positive predictive value; SUVR, standardized uptake value ratio.CC BY · PubMed Central
Extended Data Fig. 3 Comparison among fluid biomarkers on predicting Aβ PET positivity in cognitively impaired patients of the BioFINDER-2 cohort using external cut-offs. Prediction of Aβ PET positivity in cognitively impaired participants from the BioFINDER-2 cohort, using a single cut-off (a) and two cut-offs (b) approaches, respectively. In the first approach, the cut-off was calculated maximizing sensitivity fixing specificity at 90%. In the second approach, the lower cut-off was obtained by maximizing specificity with sensitivity fixed at 95%, whereas the upper cut-off was obtained by maximizing sensitivity fixing specificity at 95%. Participants that fall between these two cut-offs were classified in the intermediate group. Dots and error bars represent the actual statistic and 95%CI, respectively. The external cut-off method derives the cut-offs in independent cohorts. Plasma %p-tau217 cut-offs were derived in the Knight ADRC cohort, and CSF biomarkers were derived in the UCSF cohort. Bootstrapped differences (n = 1,000 resamples with replacement stratifying by the output) between the statistics using plasma %p-tau217 (reference) and CSF biomarkers are shown in (c) for both single and two cut-offs. A horizontal dashed line is plotted at zero representing the lack of difference between plasma and CSF biomarkers. We considered plasma and CSF biomarkers clinically equivalent if the 95%CI of the mean difference included zero and clinically superior if it did not include zero and favored plasma (>0). Differences in number of participants in the intermediate group have been scaled to a maximum of one to be comparable to the other differences. Dots and error bars represent the mean and 95%CI estimate from a bootstrapped sample. Vertical dashed lines represent the maximal statistical value possible (1). For the intermediate values plots, coloured bars represent the actual percentage and error bar the 95%CI. Aβ PET positivity was assessed as Centiloids≥37. Abbreviations: Aβ, amyloid-β, CI, confidence interval; CSF, cerebrospinal fluid; NPV, negative predictive value; PPV, positive predictive value.
Extended Data Fig. 3 Comparison among fluid biomarkers on predicting Aβ PET positivity in cognitively impaired patients of the BioFINDER-2 cohort using external cut-offs. Prediction of Aβ PET positivity in cognitively impaired participants from the BioFINDER-2 cohort, using a single cut-off (a) and two cut-offs (b) approaches, respectively. In the first approach, the cut-off was calculated maximizing sensitivity fixing specificity at 90%. In the second approach, the lower cut-off was obtained by maximizing specificity with sensitivity fixed at 95%, whereas the upper cut-off was obtained by maximizing sensitivity fixing specificity at 95%. Participants that fall between these two cut-offs were classified in the intermediate group. Dots and error bars represent the actual statistic and 95%CI, respectively. The external cut-off method derives the cut-offs in independent cohorts. Plasma %p-tau217 cut-offs were derived in the Knight ADRC cohort, and CSF biomarkers were derived in the UCSF cohort. Bootstrapped differences (n = 1,000 resamples with replacement stratifying by the output) between the statistics using plasma %p-tau217 (reference) and CSF biomarkers are shown in (c) for both single and two cut-offs. A horizontal dashed line is plotted at zero representing the lack of difference between plasma and CSF biomarkers. We considered plasma and CSF biomarkers clinically equivalent if the 95%CI of the mean difference included zero and clinically superior if it did not include zero and favored plasma (>0). Differences in number of participants in the intermediate group have been scaled to a maximum of one to be comparable to the other differences. Dots and error bars represent the mean and 95%CI estimate from a bootstrapped sample. Vertical dashed lines represent the maximal statistical value possible (1). For the intermediate values plots, coloured bars represent the actual percentage and error bar the 95%CI. Aβ PET positivity was assessed as Centiloids≥37. Abbreviations: Aβ, amyloid-β, CI, confidence interval; CSF, cerebrospinal fluid; NPV, negative predictive value; PPV, positive predictive value.CC BY · PubMed Central

Verification

Claims the paper makes

26 Valid · 2 Not valid · 3 Not checked · 66 Own results and interpretations

51 more claims · 6 with their cited sources checked

Create a free account to see all 97 claims and to verify the 5 references still open.

See all claims — free account
  • Probably not a substantial claim. 20
  • It may state two separate claims as one. 26

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 72 references

Cited by

See all 448

Metadata

Authors
Barthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., Li, Y., La Joie, R., Benzinger, T. L. S., Morris, J. C., Mattsson-Carlgren, N., Palmqvist, S., Ossenkoppele, R., Rabinovici, G. D., Stomrud, E., Bateman, R. J., & Hansson, O.
Affiliations
  • Washington University in St. Louis (US)
  • Lund University (SE)
  • University of California, San Francisco (US)
Corresponding author
  • Bateman, Randall J.
  • Hansson, Oskar
Venue
Nature Medicine
Published
2024-02-21
Volume
30
Issue
4
Pages
1085-1095
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4392013406
Cited by
448
References
72
Citations by year
2026: 146 · 2025: 197 · 2024: 105
FWCI
131.02
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • Lund University Publications (Lund University) (submittedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
Funders
  • Alzheimer's Association (AARF-22-972612, ZEN24-1069572, AARF-22, ZEN-21-848216, SG-23-1061717)
  • Cure Alzheimer's Fund
  • Australian Government (2022-Projekt0080)
  • GHR Foundation (2022-00775)
  • Alzheimer's Research Trust
  • European Commission (HORIZON2020)
  • Lunds Universitet (AF-980907)
  • Knut och Alice Wallenbergs Stiftelse ((2022-0231), 2022-Projekt0080, 2022-00775, AF-980907, 2022-1259, FO2021-0293, 2020-O000028, 1412/22)
  • Vetenskapsrådet (ERAPERMED2021-184, 2022-00775, 2022-Projekt0080, FO2021-0293, AF-980907, 1412/22, 2020-O000028, 2022-1259)
  • Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-O000028)
  • Alzheimerfonden (AF-980942, AF‐980907)
  • Skånes universitetssjukhus (2022-1259, 2020-O000028, 2022-Projekt0080)
  • National Institutes of Health
  • Parkinsonfonden (1412/22)
  • Avid Radiopharmaceuticals
  • Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis (P30 AG066444, P01AG003991, P01AG026276)
  • National Institute on Aging (AG057195, U01AG057195, R56AG061900, P01AG003991, AG062422, RF1AG061900, P30AG066444, P30AG062422, R01AG083740, R35AG072362, R01AG070941, P01AG026276)
  • HORIZON EUROPE Marie Sklodowska-Curie Actions (101061836)
  • HORIZON EUROPE European Research Council (101096455)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
Alzheimer's disease, blood biomarkers, plasma p-tau217, cerebrospinal fluid biomarkers, amyloid-beta, tau pathology, amyloid PET, tau PET, mild cognitive impairment, mild dementia, diagnostic accuracy
MeSH terms
Alzheimer Disease, Hematologic Tests, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. https://app.cochat.ai/papers/10.1038/s41591-024-02869-z
The paper
Barthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., Li, Y., La Joie, R., Benzinger, T. L. S., Morris, J. C., Mattsson-Carlgren, N., Palmqvist, S., Ossenkoppele, R., Rabinovici, G. D., Stomrud, E., . . . Hansson, O. (2024). Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. Nature Medicine. https://doi.org/10.1038/s41591-024-02869-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.